Full-Time
Mechanical Engineer
Fluidics/Perfusion
UntilLabs
51-200 employees
Advances reversible organ cryopreservation technology
Compensation Overview
$120k - $200k/yr
San Francisco Bay Area, CA, USA
In Person
On-site in the Bay Area.
Bachelor's
 Mechanical Engineering (1) |
|---|
Get referred to UntilLabs
See people who can refer or advise you
- Deep understanding of heat and mass transfer principles.
- Experience designing fluidic systems for perfusion and heat exchangers.
- Ability to work autonomously across the full engineering stack, including electromechanical design and fabrication, control software, and physical modeling.
- Develop perfusion systems, cryoprotectant formulations, and vitrification and rewarming hardware for organ-scale reversible cryopreservation.
- Three or more years of experience or graduate-level experience in Mechanical Engineering, Physics, or an equivalent field.
- Experience with organ perfusion in a research or clinical context.
- Experience working in a startup.
UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
San Francisco, California
Founded
2024
Get referred to UntilLabs
See people who can refer or advise you
Simplify's Take
What believers are saying
- 2026 hiring spans perfusion, cardiac biology, and organ perfusion, signaling active R&D expansion.
- Pig organ isolation and ex-vivo evaluation roles suggest near-term preclinical organ validation.
- The 2026 patent strengthens defensibility around cryoprotectants, vitrification, and rewarming hardware.
What critics are saying
- X-Therma already has FDA Breakthrough status and 120-hour kidney preservation claims.
- Until still has no public human transplant data, leaving commercialization unproven.
- Whole-body cryopreservation messaging invites regulatory scrutiny and distracts from organ preservation execution.
What makes UntilLabs unique
- Founders Fund, Lux, and Field backed Until Labs' 2025 $58M Series A.
- Until's 2026 site says it has raised $100M+ and is hiring.
- Its patent for reversible cryopreservation covers perfusion, pressure, and volumetric rewarming.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Flexible Work Hours
Paid Holidays
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Commuter Benefits
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 7%1 year growth
↑ 7%2 year growth
↑ 16%Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.
Fenwick represents Until Labs in $58M Series A funding.